Skip to main content
SpringerLink
Log in

Percutaneous radiofrequency ablation therapy for hepatocellular carcinoma: a proposed new grading system for the ablative margin and prediction of local tumor progression and its validation

  • Original Article—Liver, Pancreas, and Biliary Tract
  • Published:
Journal of Gastroenterology Aims and scope Submit manuscript

Abstract

Background

In the present study we classified the radicality of percutaneous radiofrequency thermal ablation (RFA) therapy according to the extent of the ablated margin. We measured the local recurrence rate for each radicality grade to evaluate the significance of the grading system in assessing the therapeutic effectiveness of RFA and predicting local tumor progression.

Methods

This retrospective study involved 269 patients with solitary hypervascular hepatocellular carcinoma who had undergone RFA. The mean ± SD observation period after RFA, number of treatment sessions, and tumor diameter were 25.7 ± 19.9 months, 1.2 ± 0.5, and 2.1 ± 0.7 cm, respectively. Patients were evaluated using dynamic computed tomography. We classified the radicality of RFA treatment into four grades (R grades: A, B, C, and D) according to the extent of the ablated tumor margin, calculated the post-RFA cumulative local recurrence rate for each R grade, and analyzed the factors (patient characteristics, biochemical data, contiguous vessels, and tumor marker) contributing to local recurrence.

Results

The cumulative local recurrence rates at 3 years were 6.7, 17.6, 55.8, and 82.2% for Grades A, B, C, and D, respectively. Using univariate analysis, R grade, tumor size (>2 cm), and des-γ-carboxy prothrombin (DCP) (>200 mAU/mL) were shown to be significant factors contributing to local recurrence. However, using multivariate analysis, only the R grade was found to be a significant independent factor.

Conclusions

The proposed R grading method is a valid and useful method for assessing treatment efficacy, and for predicting local tumor progression after RFA.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Rossi S, Di Stasi M, Buscarini E, et al. Percutaneous RF interstitial thermal ablation in the treatment of hepatic cancer. AJR Am J Roentgenol. 1996;167:759–68.

    PubMed  CAS  Google Scholar 

  2. Rossi S, Fornari F, Buscarini E, et al. Percutaneous ultrasound-guided radiofrequency electrocautery for the treatment of small hepatocellular carcinoma. J Interv Radiol. 1993;8:97–103.

    Google Scholar 

  3. Rossi S, Di Stasi M, Buscarini E, et al. Percutaneous radiofrequency interstitial thermal ablation in the treatment of small hepatocellular carcinoma. Cancer J Sci Am. 1995;1:73–81.

    PubMed  CAS  Google Scholar 

  4. Curley SA, Izzo F, Ellis LM, et al. Radiofrequency ablation of hepatocellular carcinoma in 110 patients with cirrhosis. Ann Surg. 2000;232:1694–702.

    Article  Google Scholar 

  5. Allgaier HP, Deibert P, Zuber I, et al. Percutaneous radiofrequency interstitial thermal ablation of small hepatocellular carcinoma. Lancet. 1999;353:1676–7.

    Article  PubMed  CAS  Google Scholar 

  6. Lencioni R. Loco-regional treatment of hepatocellular carcinoma. Hepatology. 2010;52:762–73.

    Article  PubMed  CAS  Google Scholar 

  7. Higuchi T, Kikuchi M, Okazaki M. Hepatocellular carcinoma after transcatheter hepatic arterial embolization. A histopathologic study of 84 resected cases. Cancer. 1994;73:2259–67.

    Article  PubMed  CAS  Google Scholar 

  8. Lin SM, Lin CJ, Lin CC, et al. Randomised controlled trial comparing percutaneous radiofrequency thermal ablation, percutaneous ethanol injection, and percutaneous acetic acid injection to treat hepatocellular carcinoma of 3 cm or less. Gut. 2005;54:1151–6.

    Article  PubMed  CAS  Google Scholar 

  9. Shiina S, Teratani T, Obi S, et al. A randomized controlled trial of radiofrequency ablation with ethanol injection for small hepatocellular carcinoma. Gastroenterology. 2005;129:122–30.

    Article  PubMed  Google Scholar 

  10. Lencioni RA, Allgaier HP, Cioni D, et al. Small hepatocellular carcinoma in cirrhosis: randomized comparison of radio-frequency thermal ablation versus percutaneous ethanol injection. Radiology. 2003;228:235–40.

    Article  PubMed  Google Scholar 

  11. Izumi N. Recent advances of radiofrequency ablation for early hepatocellular carcinoma. J Gastroenterol Hepatol. 2011;26(Suppl 1):115–22.

    Article  PubMed  Google Scholar 

  12. Liu CH, Arellano RS, Uppot RN, et al. Radiofrequency ablation of hepatic tumors: effect of post-ablation margin on local tumor progression. Eur Radiol. 2010;20:877–85.

    Article  PubMed  Google Scholar 

  13. Kim YS, Rhim H, Cho OK, et al. Intrahepatic recurrence after percutaneous radiofrequency ablation of hepatocellular carcinoma: analysis of the pattern and risk factors. Eur J Radiol. 2006;59:432–41.

    Article  PubMed  CAS  Google Scholar 

  14. Kim YS, Lee WJ, Rhim H, et al. The minimal ablative margin of radiofrequency ablation of hepatocellular carcinoma (>2 and <5 cm) needed to prevent local tumor progression: 3D quantitative assessment using CT image fusion. AJR Am J Roentgenol. 2010;195:758–65.

    Article  PubMed  Google Scholar 

  15. Ikeda K, Kobayashi M, Saitoh S, et al. Cost-effectiveness of radiofrequency ablation and surgical therapy for small hepatocellular carcinoma of 3 cm or less in diameter. Hepatol Res. 2005;33:241–9.

    Article  PubMed  Google Scholar 

  16. Nakazawa T, Kokubu S, Shibuya A, et al. Radiofrequency ablation of hepatocellular carcinoma: correlation between local tumor progression after ablation and ablative margin. AJR Am J Roentgenol. 2007;188:480–8.

    Article  PubMed  Google Scholar 

  17. Tateishi R, Shiina S, Omata M, et al. Percutaneous radiofrequency ablation for hepatocellular carcinoma. An analysis of 1000 cases. Cancer. 2005;103:1201–9.

    Article  PubMed  Google Scholar 

  18. Takahashi S, Kudo M, Chung H, et al. Initial treatment is essential to improve survival in patients with hepatocellular carcinoma who underwent curative radiofrequency ablation therapy. Oncology. 2007;72(Suppl 1):98–103.

    Article  PubMed  Google Scholar 

  19. Morimoto M, Numata K, Sugimori K, et al. Successful initial ablation therapy contributes to survival in patients with hepatocellular carcinoma. World J Gastroenterol. 2007;13:1003–9.

    PubMed  CAS  Google Scholar 

  20. Goldberg SN, Grassi CJ, Cardella JF, Society of International Radiology Technology Assessment Committee, International Working Group on Image Guided Tumor Ablation, et al. Image guided tumor ablation: standardization of terminology and reporting criteria. Radiology. 2005;235:728–39.

    Article  PubMed  Google Scholar 

  21. Goldberg SN, Charboneau JW, Dodd GD 3rd, et al. Image-guided tumor ablation: proposal for standardization of terms and reporting criteria. Radiology. 2003;228:335–45.

    Article  PubMed  Google Scholar 

  22. Arii S, Yamaoka Y, Futagawa S, et al. Results of surgical and nonsurgical treatment for small-sized hepatocellular carcinomas: a retrospective and nation-wide survey in Japan. The Liver Cancer Group of Japan. Hepatology. 2000;32:1224–9.

    Article  PubMed  CAS  Google Scholar 

  23. Chen MS, Li JQ, Zheng Y, et al. A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma. Ann Surg. 2006;242:36–42.

    Google Scholar 

  24. Zytoon AA, Ishi H, Murakami K, et al. Recurrence-free survival after radiofrequency ablation of hepatocellular carcinoma. A registry report of the impact of risk factors on outcome. Jpn J Clin Oncol. 2007;37:658–72.

    Article  PubMed  Google Scholar 

  25. Murakami T, Ishimaru H, Sakamoto I, et al. Percutaneous radiofrequency ablation and transcatheter arterial chemoembolization for hypervascular hepatocellular carcinoma: rate and risk factors for local recurrence. Cardiovasc Interv Radiol. 2007;30:696–704.

    Article  Google Scholar 

  26. Chen MH, Wu W, Yang W, et al. The use of contrast-enhanced ultrasonography in the selection of patients with hepatocellular carcinoma for radio frequency ablation therapy. J Ultrasound Med. 2007;26:1055–63.

    PubMed  Google Scholar 

  27. Osaki Y, Suginosita Y, Kimura T, et al. Usefulness of real-time virtual sonography (RVS) in treatment of hepatocellular carcinoma. Medix. 2005;42:15–20.

    Google Scholar 

  28. Kobayashi M, Ikeda K, Kawamura Y, et al. High serum des-gamma-carboxy prothrombin level predicts poor prognosis after radiofrequency ablation of hepatocellular carcinoma. Cancer. 2009;115:571–80.

    Article  PubMed  CAS  Google Scholar 

  29. Ikeda K, Kobayashi M, Seko Y, et al. Administration of interferon for two or more years decreases early stage hepatocellular carcinoma recurrence rate after radical ablation: a retrospective study of hepatitis C virus-related liver cancer. Hepatol Res. 2010;40:1168–75.

    Article  PubMed  Google Scholar 

  30. Okusaka T, Okada S, Ueno H, et al. Satellite lesions in patients with small hepatocellular carcinoma with reference to clinicopathologic features. Cancer. 2002;95:1931–7.

    Article  PubMed  Google Scholar 

Download references

Conflict of interest

The authors declare that they have no conflict of interest.

Author information

Authors and Affiliations

  1. Department of Gastroenterology and Hepatology, Osaka Red Cross Hospital, 5-30 Fudegasaki-cho, Tennoji-ku, Osaka, 543-0027, Japan

    Hiroki Nishikawa, Tadashi Inuzuka, Haruhiko Takeda, Jun Nakajima, Azusa Sakamoto, Sinichiro Henmi, Fumihiro Matsuda, Yuji Eso, Tetsuro Ishikawa, Sumio Saito, Ryuichi Kita, Toru Kimura & Yukio Osaki

Authors
  1. Hiroki Nishikawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Tadashi Inuzuka
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Haruhiko Takeda
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jun Nakajima
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Azusa Sakamoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Sinichiro Henmi
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Fumihiro Matsuda
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Yuji Eso
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Tetsuro Ishikawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Sumio Saito
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Ryuichi Kita
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Toru Kimura
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Yukio Osaki
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hiroki Nishikawa.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Nishikawa, H., Inuzuka, T., Takeda, H. et al. Percutaneous radiofrequency ablation therapy for hepatocellular carcinoma: a proposed new grading system for the ablative margin and prediction of local tumor progression and its validation. J Gastroenterol 46, 1418–1426 (2011). https://doi.org/10.1007/s00535-011-0452-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00535-011-0452-4

Keywords

Search

Navigation